Polypid Ltd Stock News

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance

Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals ​to commercialise a drug aimed at preventing surgical ‌site infections in the U.S. and Canada, under which it could receive more than $320 million.

PETACH TIKVA, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the “Agreement”) with Azurity Pharmaceuticals (“Azurity”), a privately held specia...

If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections

PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Co...

PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.